Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms

Brain Research Bulletin

Volumn 86, Issue 1-2, 2011, Pages 118-122

  Shahidi, Siamak ^a,b   Hasanein, Parisa ^c  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BU ALI SINA UNIVERSITY   (Iran)

Author keywords

Endocannabinoid; Morphine withdrawal; Rats; URB597

Indexed keywords

CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; MORPHINE; NALOXONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; JUMPING; LICKING; LOW DRUG DOSE; MALE; MORPHINE ADDICTION; NEUROMODULATION; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; RAT; STANDING; TREMOR; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

AMIDOHYDROLASES; ANIMALS; BEHAVIOR, ANIMAL; BENZAMIDES; CARBAMATES; ENDOCANNABINOIDS; HUMANS; MALE; MORPHINE DEPENDENCE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 80051579063     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.06.019     Document Type: Article

References (47)

1. Bhargava H.N. Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology (Berl.) 1976, 49:267-270.
2. Bilbao A., Cippitelli A., Martin A.B., Granado N., Ortiz O., Bezard E., Chen J.F., Navarro M., Rodriguez de F.F., Moratalla R. Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice. Psychopharmacology (Berl.) 2006, 185:160-168.
3. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
4. Diaz S.L., Kemmling A.K., Rubio M.C., Balerio G.N. Morphine withdrawal syndrome: involvement of the dopaminergic system in prepubertal male and female mice. Pharmacol. Biochem. Behav. 2005, 82:601-607.
5. Dizgah I.M., Karimian S.M., Zarrindast M.R., Sohanaki H. Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats. Neuroreport 2005, 16:1683-1686.
6. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 2005, 313:352-358.
7. Fuertes G., Laorden M.L., Milanes M.V. Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal. Neuroendocrinology 2000, 71:60-67.
8. Funada M., Shippenberg T.S. Differential involvement of D1 and D2 dopamine receptors in the expression of morphine withdrawal signs in rats. Behav. Pharmacol. 1996, 7:448-453.
9. Fundytus M.E., Ritchie J., Coderre T.J. Attenuation of morphine withdrawal symptoms by subtype-selective metabotropic glutamate receptor antagonists. Br. J. Pharmacol. 1997, 120:1015-1020.
10. Gaetani S., Dipasquale P., Romano A., Righetti L., Cassano T., Piomelli D., Cuomo V. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int. Rev. Neurobiol. 2009, 85:57-72.
11. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18620-18625.
12. Hasanein P., Shahidi S., Komaki A., Mirazi N. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. Eur. J. Pharmacol. 2008, 591:132-135.
13. Hillard C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat. 2000, 61:3-18.
14. Hillard C.J., Campbell W.B. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J. Lipid Res. 1997, 38:2383-2398.
15. Hine B., Friedman E., Torrelio M., Gershon S. Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 1975, 187:443-445.
16. Justinova Z., Mangieri R.A., Bortolato M., Chefer S.I., Mukhin A.G., Clapper J.R., King A.R., Redhi G.H., Yasar S., Piomelli D., Goldberg S.R. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol. Psychiatry 2008, 64:930-937.
17. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La R.G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9:76-81.
18. Kleven M.S., Sparber S.B. Modification of quasi-morphine withdrawal with serotonin agonists and antagonists: evidence for a role of serotonin in the expression of opiate withdrawal. Psychopharmacology (Berl.) 1989, 98:231-235.
19. Kosten T.R., George T.P. The neurobiology of opioid dependence: implications for treatment. Sci. Pract. Perspect. 2002, 1:13-20.
20. Kreek M.J., Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998, 51:23-47.
21. Leal M.B., Michelin K., Souza D.O., Elisabetsky E. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-d-aspartate receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:781-785.
22. Lelevich S.V., Lelevich V.V., Novokshonov A.A. Neurotransmitter mechanisms of morphine withdrawal syndrome. Bull. Exp. Biol. Med. 2009, 148:184-187.
23. Lichtman A.H., Sheikh S.M., Loh H.H., Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther. 2001, 298:1007-1014.
24. Manwell L.A., Satvat E., Lang S.T., Allen C.P., Leri F., Parker L.A. FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR 141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol. Biochem. Behav. 2009, 94:154-162.
25. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 1999, 20:287-294.
26. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., Di M.V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34:593-606.
27. Michalska E., Malec D. Agonists and antagonists of adenosine receptors and morphine withdrawal syndrome in rats. Pol. J. Pharmacol. 1993, 45:1-9.
28. Naidu P.S., Booker L., Cravatt B.F., Lichtman A.H. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J. Pharmacol. Exp. Ther. 2009, 329:48-56.
29. Navarro M., Chowen J., Rocio A.C., del Arco I., Villanua M.A., Martin Y., Roberts A.J., Koob G.F., de Fonseca F.R. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 1998, 9:3397-3402.
30. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., Rodriguez de F.F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J. Neurosci. 2001, 21:5344-5350.
31. Navarro-Zaragoza J., Nunez C., Ruiz-Medina J., Laorden M.L., Valverde O., Milanes M.V. CRF(2) mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats. Br. J. Pharmacol. 2010, 162:851-862.
32. Nestler E.J. Molecular mechanisms of drug addiction. J. Neurosci. 1992, 12:2439-2450.
33. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 2006, 318:304-311.
34. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS. Drug Rev. 2006, 12:21-38.
35. Riahi E., Mirzaii-Dizgah I., Karimian S.M., Roodsari H.R., Dehpour A.R. Attenuation of morphine withdrawal signs by a GABAB receptor agonist in the locus coeruleus of rats. Behav. Brain Res. 2009, 196:11-14.
36. Rodriguez de F.F., Del Arco I., Bermudez-Silva F.J., Bilbao A., Cippitelli A., Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005, 40:2-14.
37. Sagar D.R., Kendall D.A., Chapman V. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br. J. Pharmacol. 2008, 155:1297-1306.
38. Scherma M., Panlilio L.V., Fadda P., Fattore L., Gamaleddin I., Le F.B., Justinova Z., Mikics E., Haller J., Medalie J., Stroik J., Barnes C., Yasar S., Tanda G., Piomelli D., Fratta W., Goldberg S.R. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J. Pharmacol. Exp. Ther. 2008, 327:482-490.
39. Schuelert N., Johnson M.P., Oskins J.L., Jassal K., Chambers M.G., McDougall J.J. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain 2010, 152:975-981.
40. Solinas M., Justinova Z., Goldberg S.R., Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J. Neurochem. 2006, 98:408-419.
41. Solinas M., Tanda G., Justinova Z., Wertheim C.E., Yasar S., Piomelli D., Vadivel S.K., Makriyannis A., Goldberg S.R. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J. Pharmacol. Exp. Ther. 2007, 321:370-380.
42. Tanda G., Pontieri F.E., Di C.G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276:2048-2050.
43. Vela G., Ruiz-Gayo M., Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995, 34:665-668.
44. Wegener N., Koch M. Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry 2009, 42(Suppl. 1):S79-S86.
45. Yamaguchi T., Hagiwara Y., Tanaka H., Sugiura T., Waku K., Shoyama Y., Watanabe S., Yamamoto T. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res. 2001, 909:121-126.
46. Zarrindast M.R., Naghipour B., Roushan-zamir F., Shafaghi B. Effects of adenosine receptor agents on the expression of morphine withdrawal in mice. Eur. J. Pharmacol. 1999, 369:17-22.
47. Zhu H., Barr G.A. The role of AMPA and metabotropic glutamate receptors on morphine withdrawal in infant rats. Int. J. Dev. Neurosci. 2004, 22:379-395.